Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 362

The DOI matches its Crossref record; 479 of the 479 references it cites were found in a registry or an index.

Type 2 immunity in allergic diseases

Open access
Ogulur, Ismail, Mitamura, Yasutaka, Yazici, Duygu, Pat, Yagiz, Ardicli, Sena, Li, Manru, D’Avino, Paolo, Beha, Carina, Babayev, Huseyn, Zhao, Bingjie, Zeyneloglu, Can, Giannelli Viscardi, Oliva, Ardicli, Ozge, Kiykim, Ayca, Garcia-Sanchez, Asuncion, Lopez, Juan-Felipe, Shi, Li-li, Yang, Minglin, Schneider, Stephan R., Skolnick, Stephen, Dhir, Raja, Radzikowska, Urszula, Kulkarni, Abhijeet J., Imam, Manal Bel, Veen, Willem van de, Sokolowska, Milena, Martin-Fontecha, Mar, Palomares, Oscar, Nadeau, Kari C., Akdis, Mubeccel, Akdis, Cezmi A.·2025·Cellular & Molecular Immunology

Abstract

Significant advancements have been made in understanding the cellular and molecular mechanisms of type 2 immunity in allergic diseases such as asthma, allergic rhinitis, chronic rhinosinusitis, eosinophilic esophagitis (EoE), food and drug allergies, and atopic dermatitis (AD). Type 2 immunity has evolved to protect against parasitic diseases and toxins, plays a role in the expulsion of parasites and larvae from inner tissues to the lumen and outside the body, maintains microbe-rich skin and mucosal epithelial barriers and counterbalances the type 1 immune response and its destructive effects. During the development of a type 2 immune response, an innate immune response initiates starting from epithelial cells and innate lymphoid cells (ILCs), including dendritic cells and macrophages, and translates to adaptive T and B-cell immunity, particularly IgE antibody production. Eosinophils, mast cells and basophils have effects on effector functions. Cytokines from ILC2s and CD4+ helper type 2 (Th2) cells, CD8 + T cells, and NK-T cells, along with myeloid cells, including IL-4, IL-5, IL-9, and IL-13, initiate and sustain allergic inflammation via T cell cells, eosinophils, and ILC2s; promote IgE class switching; and open the epithelial barrier. Epithelial cell activation, alarmin release and barrier dysfunction are key in the development of not only allergic diseases but also many other systemic diseases. Recent biologics targeting the pathways and effector functions of IL4/IL13, IL-5, and IgE have shown promising results for almost all ages, although some patients with severe allergic diseases do not respond to these therapies, highlighting the unmet need for a more detailed and personalized approach.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41423-025-01261-2

Cites

479 of 479 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 479 references

Cited by

See all 362

Metadata

Authors
Ogulur, I., Mitamura, Y., Yazici, D., Pat, Y., Ardicli, S., Li, M., D’Avino, P., Beha, C., Babayev, H., Zhao, B., Zeyneloglu, C., Giannelli Viscardi, O., Ardicli, O., Kiykim, A., Garcia-Sanchez, A., Lopez, J.-F., Shi, L.-L., Yang, M., Schneider, S. R., Skolnick, S., Dhir, R., Radzikowska, U., Kulkarni, A. J., Imam, M. B., Veen, W. V. D., Sokolowska, M., Martin-Fontecha, M., Palomares, O., Nadeau, K. C., Akdis, M., & Akdis, C. A.
Venue
Cellular & Molecular Immunology
Published
2025-02-17
Volume
22
Issue
3
Pages
211-242
ISSN
  • 1672-7681 (ISSN-L)
  • 2042-0226
OpenAlex
W4407638922
Cited by
362
References
479
FWCI
107.61
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Type 2 immunity in allergic diseases. https://app.cochat.ai/papers/10.1038/s41423-025-01261-2
The paper
Ogulur, I., Mitamura, Y., Yazici, D., Pat, Y., Ardicli, S., Li, M., D’Avino, P., Beha, C., Babayev, H., Zhao, B., Zeyneloglu, C., Giannelli Viscardi, O., Ardicli, O., Kiykim, A., Garcia-Sanchez, A., Lopez, J.-F., Shi, L.-L., Yang, M., Schneider, S. R., . . . Akdis, C. A. (2025). Type 2 immunity in allergic diseases. Cellular & Molecular Immunology. https://doi.org/10.1038/s41423-025-01261-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.